Literature DB >> 20510874

Promoter hypomethylation contributes to the expression of MUC3A in cancer cells.

Sho Kitamoto1, Norishige Yamada, Seiya Yokoyama, Izumi Houjou, Michiyo Higashi, Suguru Yonezawa.   

Abstract

MUC3A is a membrane-bound glycoprotein that is aberrantly expressed in carcinomas and is a risk factor for a poor prognosis. However, the exact mechanism of MUC3A expression has yet to be clarified. Here, we provide the first evidence that MUC3A gene expression is controlled by the CpG methylation status of the proximal promoter region. We show that the DNA methylation pattern is intimately correlated with MUC3A expression in breast, lung, pancreas and colon cancer cell lines. The DNA methylation status of 30CpG sites from -660 to +273 was mapped using MassARRAY analysis. MUC3A-negative cancer cell lines and those with low MUC3A expression (e.g., MCF-7) were highly methylated in the proximal promoter region, corresponding to 9CpG sites (-345 to -75bp), whereas MUC3A-positive cell lines (e.g., LS174T) had low methylation levels. Moreover, 5-aza-2'-deoxycytidine and trichostatin A treatment of MUC3A-negative cells or those with low MUC3A expression caused elevation of MUC3A mRNA. Our results suggest that DNA hypomethylation in the 5'-flanking region of the MUC3A gene plays an important role in MUC3A expression in carcinomas of various organs. An understanding of epigenetic changes in MUC3A may contribute to the diagnosis of carcinogenic risk and to prediction of outcome in patients with cancer. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20510874     DOI: 10.1016/j.bbrc.2010.05.124

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  DNA methylation and histone H3-K9 modifications contribute to MUC17 expression.

Authors:  Sho Kitamoto; Norishige Yamada; Seiya Yokoyama; Izumi Houjou; Michiyo Higashi; Masamichi Goto; Surinder K Batra; Suguru Yonezawa
Journal:  Glycobiology       Date:  2010-10-06       Impact factor: 4.313

2.  Expression of MUC17 is regulated by HIF1α-mediated hypoxic responses and requires a methylation-free hypoxia responsible element in pancreatic cancer.

Authors:  Sho Kitamoto; Seiya Yokoyama; Michiyo Higashi; Norishige Yamada; Shyuichiro Matsubara; Sonshin Takao; Surinder K Batra; Suguru Yonezawa
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

3.  The application of methylation specific electrophoresis (MSE) to DNA methylation analysis of the 5' CpG island of mucin in cancer cells.

Authors:  Seiya Yokoyama; Sho Kitamoto; Norishige Yamada; Izumi Houjou; Tamotsu Sugai; Shin-ichi Nakamura; Yoshifumi Arisaka; Kyoichi Takaori; Michiyo Higashi; Suguru Yonezawa
Journal:  BMC Cancer       Date:  2012-02-14       Impact factor: 4.430

4.  Epigenetic regulation of mucin genes in human cancers.

Authors:  Norishige Yamada; Sho Kitamoto; Seiya Yokoyama; Tomofumi Hamada; Masamichi Goto; Hideaki Tsutsumida; Michiyo Higashi; Suguru Yonezawa
Journal:  Clin Epigenetics       Date:  2011-05-01       Impact factor: 6.551

5.  A comprehensive expression analysis of mucins in appendiceal carcinoma in a multicenter study: MUC3 is a novel prognostic factor.

Authors:  Hiroaki Shibahara; Michiyo Higashi; Seiya Yokoyama; Karine Rousseau; Iwao Kitazono; Masahiko Osako; Hiroshi Shirahama; Yukie Tashiro; Yasuhiro Kurumiya; Michihiko Narita; Shingo Kuze; Hiroshi Hasagawa; Takehito Kato; Hitoshi Kubota; Hideaki Suzuki; Toshiyuki Arai; Yu Sakai; Norihiro Yuasa; Masahiko Fujino; Shinji Kondo; Yoshichika Okamoto; Tatsuyoshi Yamamoto; Takashi Hiromatsu; Eiji Sasaki; Kazuhisa Shirai; Satoru Kawai; Koutarou Hattori; Hideki Tsuji; Osamu Okochi; Masaki Sakamoto; Akinobu Kondo; Naomi Konishi; Surinder K Batra; Suguru Yonezawa
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

6.  Serum mucin 3A as a potential biomarker for extrahepatic cholangiocarcinoma.

Authors:  Jing Wang; Haibin Zhou; Yucheng Wang; Haitao Huang; Jing Yang; Weigang Gu; Xiaofeng Zhang; Jianfeng Yang
Journal:  Saudi J Gastroenterol       Date:  2020 May-Jun       Impact factor: 2.485

7.  Differential expression study of circular RNAs in exosomes from serum and urine in patients with idiopathic membranous nephropathy.

Authors:  Hualin Ma; Ying Xu; Rongrong Zhang; Baochun Guo; Shuyan Zhang; Xinzhou Zhang
Journal:  Arch Med Sci       Date:  2019-04-30       Impact factor: 3.318

8.  Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.

Authors:  Seiya Yokoyama; Michiyo Higashi; Sho Kitamoto; Monika Oeldorf; Uwe Knippschild; Marko Kornmann; Kosei Maemura; Hiroshi Kurahara; Edwin Wiest; Tomofumi Hamada; Ikumi Kitazono; Yuko Goto; Takashi Tasaki; Tsubasa Hiraki; Kazuhito Hatanaka; Yuko Mataki; Hiroki Taguchi; Shinichi Hashimoto; Surinder K Batra; Akihide Tanimoto; Suguru Yonezawa; Michael A Hollingsworth
Journal:  Oncotarget       Date:  2016-07-05

9.  Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.

Authors:  Tian Niu; Yidong Liu; Yuan Zhang; Qiang Fu; Zheng Liu; Zewei Wang; Hangcheng Fu; Jiejie Xu; Kun Liu
Journal:  Oncotarget       Date:  2016-08-02

10.  Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Authors:  Fang Liu; Zhe Wang; Xiaoge Zhou; Qing Liu; Gang Chen; Hualiang Xiao; Weihua Yin; Shigeo Nakamura; Huilan Rao
Journal:  PLoS One       Date:  2018-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.